Editas Medicine

About Editas Medicine

Editas Medicine is dedicated to harnessing the power of CRISPR gene editing to develop a robust pipeline of transformative and durable genomic medicines for people with serious diseases worldwide. Their goal is to discover, develop, manufacture, and commercialize these medicines.

Products & Services

Gene Editing Pipeline:A broad range of experimental medicines focused on genomic treatments.

CRISPR Gene Editing Technology:A technology to revise, remove, and replace DNA in a highly targeted manner, used to develop medicines for serious diseases.

EDIT-401:An LDLR-targeted medicine nominated as the lead in vivo development candidate.

Specialties

CRISPR Gene Editing Genomic Medicine Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Monetization Financing T: - FT: Monetization Financing	A: 57000000 MR: - FA: $57 million FAN: 57000000	D: 2024-10-03 FD: 2024-10-03	1 investors

Monetization Financing Latest

2024-10-03

$57.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

U

Uyen Nguyen

Associate Director, Quality Systems

D

Deep Majithia

Associate Process Engineer, Process Development

B

Ben Diner

Senior Scientist I

P

Paul Wrighton

Senior Scientist II

M

Morgan Thompson

Scientist I, Histology and Imaging

G

Gilmore O'Neill

President and Chief Executive Officer

View 19 more team members with Pro

Unlock Full Team Directory

Recent News

Editas Medicine Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised